Rick Silva, PhD, has administrative leadership responsibility for programs to enhance the clinical and economic impact of the research enterprise at Texas A&M Health and in the Institute Bioscience and Technology- Center for Genomic and Precision Medicine. He has overseen the development of over 300 successful collaborations transactions with academic, nonprofit, and commercial organizations across the United States, Europe, and Asia, spanning start-ups to Fortune 500® companies.
Rick links faculty members and partners in the biopharma, diagnostic, and medical informatics industries. He directs a CPRIT-funded clinicogenomics core (TREC) coupled to cancer screening populations and the Interprofessional PharmacoGenomics (IPGx) registry and biobank program, a pioneering clinical science initiative that collaborates with medical informatics and laboratory medicine experts to create a clinicogenomic registry and research network for the implementation of pharmacogenomics and clinical decision support tools that leverage natural language procession, machine learning, and digital twin methods. These programs include efforts to enable federated data governance models on blockchain networks and develop data models to move health data privately and with patient agency across organizational boundaries. He is a co-I on NIH-funded GCC REACH HUB and advises several startup companies dedicated to the development of innovative pharmaceuticals. Rick holds an academic faculty appointment with the Department of Translational Medical Sciences in the College of Medicine.